Clinical trials: Tumor Markers, Biological
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Melanoma
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab.
- Trial name
- NCT02796352
- Testing
- High dose bolus interleukin-2 (HD IL2)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ahmad Tarhini
Female Breast Carcinoma
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer
Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.
- Trial name
- leptin (NCT01643148)
- Volunteers
- 88 people
- Sponsor
- Materno-Perinatal Hospital of the State of Mexico
Breast Cancer
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899548
- Testing
- DNA methylation analysis, microarray analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Invasive Papillary Carcinoma of Bladder
ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.
The purpose of the study is to assess, at control visit (V8), the ablative activity of intravesical administration of Oncofid-P-B on a papillary marker tumor on patients suffering from multiple primary and recurrent Ta G1-G2…
- Trial name
- NCT04661826
- Testing
- Oncofid-P-B
- Where
- 14 sites in Germany, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Metastatic Castration-resistant Prostate Cancer
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior…
- Trial name
- PORTER (NCT03835533)
- Testing
- NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B)
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Parker Institute for Cancer Immunotherapy
Cervical Cancer, Precancerous/Nonmalignant Condition
UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia
RATIONALE: Tretinoin may help cervical neoplasia cells develop into normal cervical cells. It is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia.
- Trial name
- IRB 1996-0189 (NCT00003598)
- Testing
- tretinoin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Michigan Rogel Cancer Center
PDAC - Pancreatic Ductal Adenocarcinoma
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.
- Trial name
- CASPER (NCT05853198)
- Testing
- ctDNA analysis
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Advanced Breast Cancer
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous…
- Trial name
- NCT04892693
- Testing
- Talazoparib Oral Capsule
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Seoul National University Hospital
Squamous Cell Carcinoma
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy. There is also evidence of improvement of progression free survival of patients with metastatic/recurrent SCC of the head and…
- Trial name
- NCT04533321
- Testing
- Afatinib
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Prostatic Adenocarcinoma
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
Gold markers implanted in the prostate are used frequently for position verification of the prostate during external-beam radiotherapy.
- Trial name
- NCT03384199
- Testing
- Dose escalation to prostate focal lesion
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Kasr El Aini Hospital
Metastatic Colorectal Cancer
Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker
Colorectal cancer patients with metastases (mCRC) at response under first-line chemotherapy are candidates for an convenient maintenance treatment.
- Trial name
- NCT02043821
- Testing
- Capecitabine
- Volunteers
- 80 people
- Sponsor
- Beijing Chao Yang Hospital
Sepsis
Dynamic Infection Kinetics for Early Diagnosis, Monitoring, and Prognostication of Sepsis in Adult Oncology Patients: Evaluating Serial Infection Biomarkers, Blood Culture Kinetics, Treatment Response, Disease Severity, and Clinical Outcomes
Dynamic Infection Kinetics as an Early Diagnostic and Monitoring Tool for Sepsis in Oncology Patients This study aims to evaluate whether changes over time in infection-related biomarkers and blood culture findings can help…
- Trial name
- NCT07795502
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Carcinoma, Hepatocellular, Marker, Biological
MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death worldwide.
- Trial name
- NCT02448056
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Chronic Atrophic Gastritis
Multi-omics Analyses on Etiology and Early Detection of Stomach Cancer Precursor Lesions
The overall aim is to utilize multi-omics approach to identify novel etiopathogenesis and early detection biomarkers for stomach cancer precursor lesions.
- Trial name
- NCT06267703
- Testing
- Metabolomic profiling
- Where
- Sweden
- Volunteers
- 12,599 people
- Sponsor
- Karolinska Institutet
Breast Cancer, Abnormal Mammogram, Unspecified
Breath Test to Predict Breast Cancer and Outcome of Mammography
To validate a breath test that predicts risk of breast cancer and an abnormal mammogram.
- Trial name
- NCT04755829
- Testing
- BreathX test for breath VOCs
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Menssana Research, Inc.
Breast Cancer, Ovarian Cancer
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT05223218
- Testing
- Schirmer strip, a Class I Medical Device typically used to test for dry eye.
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Namida Lab
Leukemia, Hodgkins Disease
Blood Samples to Evaluate Biomarkers of Donor Chimerism
We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants.
- Conditions
- Leukemia, Hodgkins Disease, Non-hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT00764829
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Biomarkers
Detection of Disease Marker Factors in Cyst Fluid
The purpose of this observational study is to examine the cyst fluid obtained after a puncture procedure performed for cyst diagnosis in participants with cystic lesions on clinical and radiological examination.The main question…
- Trial name
- NCT07171151
- Testing
- cyst fluid examination
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Harran University
Patients With Liver Metastases From Colorectal Cancer
Modelling Internal Hepatic Movement With an External Abdominal Marker
This study tests the feasibility and reproducibility of patient-specific motion models. These will be used for quantification of safe margin reduction.
- Trial name
- NCT00299299
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Royal Marsden NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.